Literature DB >> 19867879

CONCENTRATION OF THE PROTECTIVE BODIES IN ANTIPNEUMOCOCCUS SERUM BY MEANS OF SPECIFIC PRECIPITATION.

F P Gay1, H T Chickering.   

Abstract

The addition of a water-clear extract of pneumococci to homologous antiserum produces a voluminous precipitate which carries down with it the agglutinins and practically the totality of the protective bodies against pneumococcus infection in animals. This precipitate when washed and resuspended in saline solution to the original volume of serum protects as well as the whole serum. The protein content of such solutions has varied from 0.09 to 0.34 per cent., as contrasted with about 6 per cent. in the original serum. The solution of this precipitate is not necessary to insure protection, and when produced by dilute alkali (sodium hydrate) frequently destroys the immune bodies.

Entities:  

Year:  1915        PMID: 19867879      PMCID: PMC2125319          DOI: 10.1084/jem.21.4.389

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  Remarks on THE SERUM TREATMENT OF PNEUMONIA.

Authors:  R L Cecil
Journal:  Br Med J       Date:  1932-10-08

2.  Present status of serum therapy in pneumonia. 1939.

Authors:  R L Cecil
Journal:  Bull N Y Acad Med       Date:  1997

3.  ON THE PRESENCE IN ANTIPNEUMOCOCCUS SERUM OF TYPE-SPECIFIC PROTECTIVE ANTIBODY NOT NEUTRALIZED BY HOMOLOGOUS SPECIFIC SOLUBLE SUBSTANCE.

Authors:  A B Sabin
Journal:  J Exp Med       Date:  1931-01-01       Impact factor: 14.307

4.  PURIFICATION AND CRYSTALLIZATION OF DIPHTHERIA ANTITOXIN.

Authors:  J H Northrop
Journal:  J Gen Physiol       Date:  1942-01-20       Impact factor: 4.086

5.  THE PURIFICATION OF THE ANTIBODIES IN TYPE I ANTI-PNEUMOCOCCUS SERUM, AND THE CHEMICAL NATURE OF THE TYPE-SPECIFIC PRECIPITIN REACTION.

Authors:  B F Chow; W F Goebel
Journal:  J Exp Med       Date:  1935-07-31       Impact factor: 14.307

6.  THE CONCENTRATION OF THE PROTECTIVE BODIES IN ANTIPNEUMOCOCCUS SERUM. SPECIFIC PRECIPITATE EXTRACTS.

Authors:  H T Chickering
Journal:  J Exp Med       Date:  1915-08-01       Impact factor: 14.307

7.  SPECIFIC PRECIPITATION AND MOUSE PROTECTION IN TYPE I ANTIPNEUMOCOCCUS SERA.

Authors:  M Heidelberger; R H Sia; F E Kendall
Journal:  J Exp Med       Date:  1930-09-30       Impact factor: 14.307

8.  THE PRODUCTION OF ANTIPNEUMOCOCCIC SERUM.

Authors:  R Cole; H F Moore
Journal:  J Exp Med       Date:  1917-10-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.